ZA200401800B - Phenyl derivatives as factor Xa inhibitors. - Google Patents

Phenyl derivatives as factor Xa inhibitors. Download PDF

Info

Publication number: ZA200401800B
Authority: ZA; South Africa
Prior art keywords: phenyl; yloxy; oxopiperidin; aminoisoquinolin; methylpentanamide
Prior art date: 2001-08-08

Application number

ZA200401800A

Other languages

English (en)

Inventor

Dieter Dorsch

Christos Tsaklakidis

Johannes Gleitz

Bertram Cezanne

Werner Mederski

Christopher Barnes

Original Assignee

Merck Patent Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-08-08

Filing date

2004-03-04

Publication date

2005-02-04

2004-03-04 Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh

2005-02-04 Publication of ZA200401800B publication Critical patent/ZA200401800B/en

Links

125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 title claims description 74
229940123583 Factor Xa inhibitor Drugs 0.000 title description 4
-1 methylene, ethylene, propylene Chemical group 0.000 claims description 136
150000001875 compounds Chemical class 0.000 claims description 96
239000000203 mixture Substances 0.000 claims description 48
239000012453 solvate Substances 0.000 claims description 33
125000004432 carbon atom Chemical group C* 0.000 claims description 31
125000002947 alkylene group Chemical group 0.000 claims description 28
238000000034 method Methods 0.000 claims description 25
206010028980 Neoplasm Diseases 0.000 claims description 24
239000003814 drug Substances 0.000 claims description 20
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 18
239000000126 substance Substances 0.000 claims description 18
238000011282 treatment Methods 0.000 claims description 16
229910052757 nitrogen Inorganic materials 0.000 claims description 15
229920006395 saturated elastomer Polymers 0.000 claims description 15
125000004434 sulfur atom Chemical group 0.000 claims description 14
208000007536 Thrombosis Diseases 0.000 claims description 13
150000003839 salts Chemical class 0.000 claims description 13
239000002253 acid Substances 0.000 claims description 12
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 12
DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims description 11
108010074860 Factor Xa Proteins 0.000 claims description 11
125000000217 alkyl group Chemical group 0.000 claims description 11
229910052801 chlorine Inorganic materials 0.000 claims description 11
125000004430 oxygen atom Chemical group O* 0.000 claims description 11
238000002360 preparation method Methods 0.000 claims description 11
229910052731 fluorine Inorganic materials 0.000 claims description 10
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 10
125000004433 nitrogen atom Chemical group N* 0.000 claims description 10
239000004480 active ingredient Substances 0.000 claims description 9
238000002399 angioplasty Methods 0.000 claims description 9
208000010125 myocardial infarction Diseases 0.000 claims description 9
125000001140 1,4-phenylene group Chemical group [H]C1=C([H])C([*:2])=C([H])C([H])=C1[*:1] 0.000 claims description 8
206010002383 Angina Pectoris Diseases 0.000 claims description 8
206010003210 Arteriosclerosis Diseases 0.000 claims description 8
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical group O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims description 8
206010061218 Inflammation Diseases 0.000 claims description 8
206010022562 Intermittent claudication Diseases 0.000 claims description 8
206010027476 Metastases Diseases 0.000 claims description 8
208000011775 arteriosclerosis disease Diseases 0.000 claims description 8
125000002619 bicyclic group Chemical group 0.000 claims description 8
ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims description 8
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
230000004054 inflammatory process Effects 0.000 claims description 8
125000002950 monocyclic group Chemical group 0.000 claims description 8
208000037803 restenosis Diseases 0.000 claims description 8
208000019695 Migraine disease Diseases 0.000 claims description 7
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 7
125000000623 heterocyclic group Chemical group 0.000 claims description 7
206010027599 migraine Diseases 0.000 claims description 7
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 7
125000006239 protecting group Chemical group 0.000 claims description 7
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 7
108010039209 Blood Coagulation Factors Proteins 0.000 claims description 6
102000015081 Blood Coagulation Factors Human genes 0.000 claims description 6
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 6
239000003114 blood coagulation factor Substances 0.000 claims description 6
125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims description 6
125000003277 amino group Chemical group 0.000 claims description 5
229910052794 bromium Inorganic materials 0.000 claims description 5
239000003112 inhibitor Substances 0.000 claims description 5
230000002401 inhibitory effect Effects 0.000 claims description 5
230000008569 process Effects 0.000 claims description 5
125000006615 aromatic heterocyclic group Chemical group 0.000 claims description 4
239000004305 biphenyl Substances 0.000 claims description 4
235000010290 biphenyl Nutrition 0.000 claims description 4
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 4
125000001624 naphthyl group Chemical group 0.000 claims description 4
229910052760 oxygen Inorganic materials 0.000 claims description 3
125000002993 cycloalkylene group Chemical group 0.000 claims description 2
IPWFJLQDVFKJDU-UHFFFAOYSA-N pentanamide Chemical compound CCCCC(N)=O IPWFJLQDVFKJDU-UHFFFAOYSA-N 0.000 claims 13
DNSISZSEWVHGLH-UHFFFAOYSA-N butanamide Chemical compound CCCC(N)=O DNSISZSEWVHGLH-UHFFFAOYSA-N 0.000 claims 6
238000004519 manufacturing process Methods 0.000 claims 3
LSBDFXRDZJMBSC-UHFFFAOYSA-N 2-phenylacetamide Chemical compound NC(=O)CC1=CC=CC=C1 LSBDFXRDZJMBSC-UHFFFAOYSA-N 0.000 claims 2
ALBYIUDWACNRRB-UHFFFAOYSA-N hexanamide Chemical compound CCCCCC(N)=O ALBYIUDWACNRRB-UHFFFAOYSA-N 0.000 claims 2
TXLKMWUKBXZNLJ-QFIPXVFZSA-N (2s)-2-(1-aminoisoquinolin-7-yl)oxy-4-methyl-n-[4-(3-oxomorpholin-4-yl)phenyl]pentanamide Chemical compound O=C([C@@H](OC=1C=C2C(N)=NC=CC2=CC=1)CC(C)C)NC(C=C1)=CC=C1N1CCOCC1=O TXLKMWUKBXZNLJ-QFIPXVFZSA-N 0.000 claims 1
PMWYZIQLCNYWLW-UHFFFAOYSA-N 2-(1-aminoisoquinolin-7-yl)oxy-4-methyl-n-[4-(2-oxoimidazolidin-1-yl)phenyl]pentanamide Chemical compound C=1C=C2C=CN=C(N)C2=CC=1OC(CC(C)C)C(=O)NC(C=C1)=CC=C1N1CCNC1=O PMWYZIQLCNYWLW-UHFFFAOYSA-N 0.000 claims 1
QYRPPNHJZUENNT-UHFFFAOYSA-N 2-(1-aminoisoquinolin-7-yl)oxy-4-methyl-n-[4-(2-oxopiperidin-1-yl)phenyl]pentanamide Chemical compound C=1C=C2C=CN=C(N)C2=CC=1OC(CC(C)C)C(=O)NC(C=C1)=CC=C1N1CCCCC1=O QYRPPNHJZUENNT-UHFFFAOYSA-N 0.000 claims 1
KIBUVYNPXBASRV-UHFFFAOYSA-N 2-(1-aminoisoquinolin-7-yl)oxy-n-[4-(2-oxo-3-azabicyclo[2.2.2]octan-3-yl)-3-(trifluoromethyl)phenyl]pentanamide Chemical compound C1CC(C2=O)CCC1N2C(C(=C1)C(F)(F)F)=CC=C1NC(=O)C(CCC)OC1=CC=C(C=CN=C2N)C2=C1 KIBUVYNPXBASRV-UHFFFAOYSA-N 0.000 claims 1
KEWSTXKVPZRHBF-UHFFFAOYSA-N 2-(1-aminoisoquinolin-7-yl)oxy-n-[4-(2-oxopiperidin-1-yl)phenyl]butanamide Chemical compound C=1C=C2C=CN=C(N)C2=CC=1OC(CC)C(=O)NC(C=C1)=CC=C1N1CCCCC1=O KEWSTXKVPZRHBF-UHFFFAOYSA-N 0.000 claims 1
PORCYMVSXHJTBO-UHFFFAOYSA-N 2-(1-aminoisoquinolin-7-yl)oxy-n-[4-(2-oxopiperidin-1-yl)phenyl]hexanamide Chemical compound C=1C=C2C=CN=C(N)C2=CC=1OC(CCCC)C(=O)NC(C=C1)=CC=C1N1CCCCC1=O PORCYMVSXHJTBO-UHFFFAOYSA-N 0.000 claims 1
ATAGAMHJYIBPHX-UHFFFAOYSA-N 2-(1-aminoisoquinolin-7-yl)oxy-n-[4-(2-oxopiperidin-1-yl)phenyl]propanamide Chemical compound C=1C=C2C=CN=C(N)C2=CC=1OC(C)C(=O)NC(C=C1)=CC=C1N1CCCCC1=O ATAGAMHJYIBPHX-UHFFFAOYSA-N 0.000 claims 1
RSKUBALBIOHNFT-UHFFFAOYSA-N 2-(2,3-dihydro-1,4-benzodioxin-6-ylamino)-n-[3-methyl-4-(2-oxopiperidin-1-yl)phenyl]-2-phenylacetamide Chemical compound C=1C=C(N2C(CCCC2)=O)C(C)=CC=1NC(=O)C(NC=1C=C2OCCOC2=CC=1)C1=CC=CC=C1 RSKUBALBIOHNFT-UHFFFAOYSA-N 0.000 claims 1
BBBGGIFZDOEMMR-UHFFFAOYSA-N 2-(2-fluorophenyl)-2-isoquinolin-7-yloxy-n-[3-methyl-4-(2-oxopiperidin-1-yl)phenyl]acetamide Chemical compound C=1C=C(N2C(CCCC2)=O)C(C)=CC=1NC(=O)C(OC=1C=C2C=NC=CC2=CC=1)C1=CC=CC=C1F BBBGGIFZDOEMMR-UHFFFAOYSA-N 0.000 claims 1
HIEONZRCYYRXHM-UHFFFAOYSA-N 2-[(3-amino-1h-indazol-5-yl)amino]-4-methyl-n-[4-(3-oxomorpholin-4-yl)phenyl]pentanamide Chemical compound C=1C=C2NN=C(N)C2=CC=1NC(CC(C)C)C(=O)NC(C=C1)=CC=C1N1CCOCC1=O HIEONZRCYYRXHM-UHFFFAOYSA-N 0.000 claims 1
HOBSZUFPFVALAP-UHFFFAOYSA-N 2-[(3-amino-1h-indazol-5-yl)oxy]-4-methyl-n-[4-(3-oxomorpholin-4-yl)phenyl]pentanamide Chemical compound C=1C=C2NN=C(N)C2=CC=1OC(CC(C)C)C(=O)NC(C=C1)=CC=C1N1CCOCC1=O HOBSZUFPFVALAP-UHFFFAOYSA-N 0.000 claims 1
QGWPEFARZPOKIW-UHFFFAOYSA-N 2-isoquinolin-7-yloxy-n-[4-(2-oxopiperidin-1-yl)phenyl]pentanamide Chemical compound C=1C=C2C=CN=CC2=CC=1OC(CCC)C(=O)NC(C=C1)=CC=C1N1CCCCC1=O QGWPEFARZPOKIW-UHFFFAOYSA-N 0.000 claims 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 1
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 1
239000001301 oxygen Substances 0.000 claims 1
239000000546 pharmaceutical excipient Substances 0.000 claims 1
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 24
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
238000006243 chemical reaction Methods 0.000 description 18
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 15
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 15
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 13
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 10
230000015572 biosynthetic process Effects 0.000 description 10
239000012442 inert solvent Substances 0.000 description 10
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
239000000460 chlorine Substances 0.000 description 9
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
108090000190 Thrombin Proteins 0.000 description 8
230000005764 inhibitory process Effects 0.000 description 8
229960004072 thrombin Drugs 0.000 description 8
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 7
238000005755 formation reaction Methods 0.000 description 7
125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 7
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
125000002252 acyl group Chemical group 0.000 description 6
239000003146 anticoagulant agent Substances 0.000 description 6
BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 6
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
239000007858 starting material Substances 0.000 description 6
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 5
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 5
VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 5
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 5
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 4
ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 4
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 4
LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 4
DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 4
208000001435 Thromboembolism Diseases 0.000 description 4
230000004913 activation Effects 0.000 description 4
150000001298 alcohols Chemical class 0.000 description 4
239000003513 alkali Substances 0.000 description 4
229910052784 alkaline earth metal Inorganic materials 0.000 description 4
150000001408 amides Chemical class 0.000 description 4
230000002785 anti-thrombosis Effects 0.000 description 4
229940127219 anticoagulant drug Drugs 0.000 description 4
125000003118 aryl group Chemical group 0.000 description 4
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 4
150000001735 carboxylic acids Chemical class 0.000 description 4
201000010099 disease Diseases 0.000 description 4
LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 4
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 4
BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 4
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 4
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 4
125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 3
OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 3
QGJOPFRUJISHPQ-UHFFFAOYSA-N Carbon disulfide Chemical compound S=C=S QGJOPFRUJISHPQ-UHFFFAOYSA-N 0.000 description 3
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
150000007513 acids Chemical class 0.000 description 3
239000002585 base Substances 0.000 description 3
230000023555 blood coagulation Effects 0.000 description 3
229910002091 carbon monoxide Inorganic materials 0.000 description 3
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
230000015271 coagulation Effects 0.000 description 3
238000005345 coagulation Methods 0.000 description 3
150000002148 esters Chemical class 0.000 description 3
150000002170 ethers Chemical class 0.000 description 3
235000019253 formic acid Nutrition 0.000 description 3
229910052739 hydrogen Inorganic materials 0.000 description 3
238000007327 hydrogenolysis reaction Methods 0.000 description 3
238000000338 in vitro Methods 0.000 description 3
238000001727 in vivo Methods 0.000 description 3
229960004592 isopropanol Drugs 0.000 description 3
238000005259 measurement Methods 0.000 description 3
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 3
239000002904 solvent Substances 0.000 description 3
238000003786 synthesis reaction Methods 0.000 description 3
WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 2
BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 2
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 2
ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
108010048049 Factor IXa Proteins 0.000 description 2
108010014173 Factor X Proteins 0.000 description 2
102000009123 Fibrin Human genes 0.000 description 2
108010073385 Fibrin Proteins 0.000 description 2
BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 2
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 2
JLTDJTHDQAWBAV-UHFFFAOYSA-N N,N-dimethylaniline Chemical compound CN(C)C1=CC=CC=C1 JLTDJTHDQAWBAV-UHFFFAOYSA-N 0.000 description 2
SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 2
PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
108091005804 Peptidases Proteins 0.000 description 2
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
239000004365 Protease Substances 0.000 description 2
108010000499 Thromboplastin Proteins 0.000 description 2
102000002262 Thromboplastin Human genes 0.000 description 2
XSTXAVWGXDQKEL-UHFFFAOYSA-N Trichloroethylene Chemical group ClC=C(Cl)Cl XSTXAVWGXDQKEL-UHFFFAOYSA-N 0.000 description 2
229940022682 acetone Drugs 0.000 description 2
125000001931 aliphatic group Chemical group 0.000 description 2
229910001854 alkali hydroxide Inorganic materials 0.000 description 2
229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 description 2
150000001342 alkaline earth metals Chemical class 0.000 description 2
125000004453 alkoxycarbonyl group Chemical group 0.000 description 2
125000003710 aryl alkyl group Chemical group 0.000 description 2
SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 2
125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 2
239000011230 binding agent Substances 0.000 description 2
210000001772 blood platelet Anatomy 0.000 description 2
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
229910052792 caesium Inorganic materials 0.000 description 2
TVFDJXOCXUVLDH-UHFFFAOYSA-N caesium atom Chemical compound [Cs] TVFDJXOCXUVLDH-UHFFFAOYSA-N 0.000 description 2
229910052791 calcium Inorganic materials 0.000 description 2
239000011575 calcium Substances 0.000 description 2
201000011510 cancer Diseases 0.000 description 2
125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 description 2
229910052799 carbon Inorganic materials 0.000 description 2
229950005499 carbon tetrachloride Drugs 0.000 description 2
239000003054 catalyst Substances 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
150000008280 chlorinated hydrocarbons Chemical class 0.000 description 2
229960001701 chloroform Drugs 0.000 description 2
SBZXBUIDTXKZTM-UHFFFAOYSA-N diglyme Chemical compound COCCOCCOC SBZXBUIDTXKZTM-UHFFFAOYSA-N 0.000 description 2
230000002349 favourable effect Effects 0.000 description 2
229950003499 fibrin Drugs 0.000 description 2
125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
229930195733 hydrocarbon Natural products 0.000 description 2
150000002430 hydrocarbons Chemical class 0.000 description 2
239000001257 hydrogen Substances 0.000 description 2
WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
238000011065 in-situ storage Methods 0.000 description 2
SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
TWBYWOBDOCUKOW-UHFFFAOYSA-N isonicotinic acid Chemical compound OC(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-N 0.000 description 2
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
150000002576 ketones Chemical class 0.000 description 2
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 2
150000007522 mineralic acids Chemical class 0.000 description 2
230000014508 negative regulation of coagulation Effects 0.000 description 2
150000002825 nitriles Chemical class 0.000 description 2
150000002828 nitro derivatives Chemical class 0.000 description 2
LQNUZADURLCDLV-UHFFFAOYSA-N nitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC=C1 LQNUZADURLCDLV-UHFFFAOYSA-N 0.000 description 2
150000007530 organic bases Chemical class 0.000 description 2
125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 2
239000003208 petroleum Substances 0.000 description 2
235000011007 phosphoric acid Nutrition 0.000 description 2
WLJVNTCWHIRURA-UHFFFAOYSA-N pimelic acid Chemical compound OC(=O)CCCCCC(O)=O WLJVNTCWHIRURA-UHFFFAOYSA-N 0.000 description 2
229910052700 potassium Inorganic materials 0.000 description 2
239000011591 potassium Substances 0.000 description 2
230000002265 prevention Effects 0.000 description 2
239000000651 prodrug Substances 0.000 description 2
229940002612 prodrug Drugs 0.000 description 2
238000011321 prophylaxis Methods 0.000 description 2
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
230000035484 reaction time Effects 0.000 description 2
229910052708 sodium Inorganic materials 0.000 description 2
239000011734 sodium Substances 0.000 description 2
150000003460 sulfonic acids Chemical class 0.000 description 2
150000003462 sulfoxides Chemical class 0.000 description 2
VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
230000002537 thrombolytic effect Effects 0.000 description 2
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
UBOXGVDOUJQMTN-UHFFFAOYSA-N trichloroethylene Natural products ClCC(Cl)Cl UBOXGVDOUJQMTN-UHFFFAOYSA-N 0.000 description 2
239000008096 xylene Substances 0.000 description 2
BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
125000005919 1,2,2-trimethylpropyl group Chemical group 0.000 description 1
125000005940 1,4-dioxanyl group Chemical group 0.000 description 1
BVKWVMOTHUYVKL-UHFFFAOYSA-N 1-(4-amino-2-methylphenyl)piperidin-2-one Chemical compound CC1=CC(N)=CC=C1N1C(=O)CCCC1 BVKWVMOTHUYVKL-UHFFFAOYSA-N 0.000 description 1
125000006218 1-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
125000006219 1-ethylpentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
NKOGCJIYHZVBDR-UHFFFAOYSA-N 1-phenylpiperidin-2-one Chemical group O=C1CCCCN1C1=CC=CC=C1 NKOGCJIYHZVBDR-UHFFFAOYSA-N 0.000 description 1
125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
125000001462 1-pyrrolyl group Chemical group [*]N1C([H])=C([H])C([H])=C1[H] 0.000 description 1
OXQGTIUCKGYOAA-UHFFFAOYSA-N 2-Ethylbutanoic acid Chemical compound CCC(CC)C(O)=O OXQGTIUCKGYOAA-UHFFFAOYSA-N 0.000 description 1
XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical group COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 description 1
125000006176 2-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 description 1
125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 1
125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
125000005916 2-methylpentyl group Chemical group 0.000 description 1
125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
125000004485 2-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])C1([H])* 0.000 description 1
125000000389 2-pyrrolyl group Chemical group [H]N1C([*])=C([H])C([H])=C1[H] 0.000 description 1
125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 1
BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 description 1
125000005917 3-methylpentyl group Chemical group 0.000 description 1
125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
125000004575 3-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
125000001397 3-pyrrolyl group Chemical group [H]N1C([H])=C([*])C([H])=C1[H] 0.000 description 1
125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 1
125000004217 4-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC([H])([H])[H])C([H])([H])* 0.000 description 1
125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
KDDQRKBRJSGMQE-UHFFFAOYSA-N 4-thiazolyl Chemical compound [C]1=CSC=N1 KDDQRKBRJSGMQE-UHFFFAOYSA-N 0.000 description 1
125000004539 5-benzimidazolyl group Chemical group N1=CNC2=C1C=CC(=C2)* 0.000 description 1
CWDWFSXUQODZGW-UHFFFAOYSA-N 5-thiazolyl Chemical group [C]1=CN=CS1 CWDWFSXUQODZGW-UHFFFAOYSA-N 0.000 description 1
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
206010002388 Angina unstable Diseases 0.000 description 1
200000000007 Arterial disease Diseases 0.000 description 1
206010003178 Arterial thrombosis Diseases 0.000 description 1
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Natural products OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
208000021910 Cerebral Arterial disease Diseases 0.000 description 1
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
108010049003 Fibrinogen Proteins 0.000 description 1
102000008946 Fibrinogen Human genes 0.000 description 1
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
206010019233 Headaches Diseases 0.000 description 1
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
102000015636 Oligopeptides Human genes 0.000 description 1
108010038807 Oligopeptides Proteins 0.000 description 1
206010061902 Pancreatic neoplasm Diseases 0.000 description 1
102000035195 Peptidases Human genes 0.000 description 1
208000005764 Peripheral Arterial Disease Diseases 0.000 description 1
208000030831 Peripheral arterial occlusive disease Diseases 0.000 description 1
102000015795 Platelet Membrane Glycoproteins Human genes 0.000 description 1
108010010336 Platelet Membrane Glycoproteins Proteins 0.000 description 1
108010094028 Prothrombin Proteins 0.000 description 1
102100027378 Prothrombin Human genes 0.000 description 1
208000010378 Pulmonary Embolism Diseases 0.000 description 1
206010038563 Reocclusion Diseases 0.000 description 1
102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
108010022999 Serine Proteases Proteins 0.000 description 1
102000012479 Serine Proteases Human genes 0.000 description 1
108010023197 Streptokinase Proteins 0.000 description 1
208000006011 Stroke Diseases 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
108090000373 Tissue Plasminogen Activator Proteins 0.000 description 1
108050006955 Tissue-type plasminogen activator Proteins 0.000 description 1
208000007814 Unstable Angina Diseases 0.000 description 1
108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
206010047249 Venous thrombosis Diseases 0.000 description 1
CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical class [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 description 1
229960001138 acetylsalicylic acid Drugs 0.000 description 1
238000005917 acylation reaction Methods 0.000 description 1
125000002723 alicyclic group Chemical group 0.000 description 1
125000005278 alkyl sulfonyloxy group Chemical group 0.000 description 1
230000029936 alkylation Effects 0.000 description 1
238000005804 alkylation reaction Methods 0.000 description 1
BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
230000002429 anti-coagulating effect Effects 0.000 description 1
230000000259 anti-tumor effect Effects 0.000 description 1
125000003435 aroyl group Chemical group 0.000 description 1
206010003246 arthritis Diseases 0.000 description 1
125000005161 aryl oxy carbonyl group Chemical group 0.000 description 1
125000004391 aryl sulfonyl group Chemical group 0.000 description 1
125000005279 aryl sulfonyloxy group Chemical group 0.000 description 1
235000010323 ascorbic acid Nutrition 0.000 description 1
239000011668 ascorbic acid Substances 0.000 description 1
229960005070 ascorbic acid Drugs 0.000 description 1
230000003143 atherosclerotic effect Effects 0.000 description 1
229940092714 benzenesulfonic acid Drugs 0.000 description 1
MBXXQYJBFRRFCK-UHFFFAOYSA-N benzyl fluoride Chemical compound FCC1=CC=CC=C1 MBXXQYJBFRRFCK-UHFFFAOYSA-N 0.000 description 1
125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
229920002988 biodegradable polymer Polymers 0.000 description 1
239000004621 biodegradable polymer Substances 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
125000001589 carboacyl group Chemical group 0.000 description 1
229940074993 carbon disulfide Drugs 0.000 description 1
125000002843 carboxylic acid group Chemical group 0.000 description 1
235000015165 citric acid Nutrition 0.000 description 1
238000004140 cleaning Methods 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
238000004132 cross linking Methods 0.000 description 1
125000000753 cycloalkyl group Chemical group 0.000 description 1
125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
238000011161 development Methods 0.000 description 1
206010012601 diabetes mellitus Diseases 0.000 description 1
HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
150000004683 dihydrates Chemical class 0.000 description 1
MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
AFAXGSQYZLGZPG-UHFFFAOYSA-N ethanedisulfonic acid Chemical compound OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 description 1
CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
229940093499 ethyl acetate Drugs 0.000 description 1
235000019439 ethyl acetate Nutrition 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
229940012952 fibrinogen Drugs 0.000 description 1
239000011737 fluorine Substances 0.000 description 1
239000001530 fumaric acid Substances 0.000 description 1
229940052308 general anesthetics halogenated hydrocarbons Drugs 0.000 description 1
239000000174 gluconic acid Substances 0.000 description 1
235000012208 gluconic acid Nutrition 0.000 description 1
229940093915 gynecological organic acid Drugs 0.000 description 1
238000001631 haemodialysis Methods 0.000 description 1
150000008282 halocarbons Chemical class 0.000 description 1
231100000869 headache Toxicity 0.000 description 1
230000036541 health Effects 0.000 description 1
125000004836 hexamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 description 1
150000004677 hydrates Chemical class 0.000 description 1
NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
JBFYUZGYRGXSFL-UHFFFAOYSA-N imidazolide Chemical compound C1=C[N-]C=N1 JBFYUZGYRGXSFL-UHFFFAOYSA-N 0.000 description 1
208000027866 inflammatory disease Diseases 0.000 description 1
201000004332 intermediate coronary syndrome Diseases 0.000 description 1
125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
TYQCGQRIZGCHNB-JLAZNSOCSA-N l-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(O)=C(O)C1=O TYQCGQRIZGCHNB-JLAZNSOCSA-N 0.000 description 1
239000004310 lactic acid Substances 0.000 description 1
235000014655 lactic acid Nutrition 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
239000011976 maleic acid Substances 0.000 description 1
239000001630 malic acid Substances 0.000 description 1
235000011090 malic acid Nutrition 0.000 description 1
208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
230000009401 metastasis Effects 0.000 description 1
238000002406 microsurgery Methods 0.000 description 1
230000004784 molecular pathogenesis Effects 0.000 description 1
150000004682 monohydrates Chemical class 0.000 description 1
239000000178 monomer Substances 0.000 description 1
125000004312 morpholin-2-yl group Chemical group [H]N1C([H])([H])C([H])([H])OC([H])(*)C1([H])[H] 0.000 description 1
125000004572 morpholin-3-yl group Chemical group N1C(COCC1)* 0.000 description 1
125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
208000031225 myocardial ischemia Diseases 0.000 description 1
LNOPIUAQISRISI-UHFFFAOYSA-N n'-hydroxy-2-propan-2-ylsulfonylethanimidamide Chemical compound CC(C)S(=O)(=O)CC(N)=NO LNOPIUAQISRISI-UHFFFAOYSA-N 0.000 description 1
125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
239000011664 nicotinic acid Substances 0.000 description 1
235000001968 nicotinic acid Nutrition 0.000 description 1
229960003512 nicotinic acid Drugs 0.000 description 1
229910017604 nitric acid Inorganic materials 0.000 description 1
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
LYGJENNIWJXYER-UHFFFAOYSA-N nitromethane Chemical compound C[N+]([O-])=O LYGJENNIWJXYER-UHFFFAOYSA-N 0.000 description 1
229910000510 noble metal Inorganic materials 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
229940021317 other blood product in atc Drugs 0.000 description 1
WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical class C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 description 1
150000004866 oxadiazoles Chemical class 0.000 description 1
125000003232 p-nitrobenzoyl group Chemical group [N+](=O)([O-])C1=CC=C(C(=O)*)C=C1 0.000 description 1
229910052763 palladium Inorganic materials 0.000 description 1
201000002528 pancreatic cancer Diseases 0.000 description 1
208000008443 pancreatic carcinoma Diseases 0.000 description 1
230000007170 pathology Effects 0.000 description 1
125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
125000003884 phenylalkyl group Chemical group 0.000 description 1
150000003016 phosphoric acids Chemical class 0.000 description 1
125000004483 piperidin-3-yl group Chemical group N1CC(CCC1)* 0.000 description 1
125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 description 1
IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
238000004321 preservation Methods 0.000 description 1
229940039716 prothrombin Drugs 0.000 description 1
125000003373 pyrazinyl group Chemical group 0.000 description 1
125000002206 pyridazin-3-yl group Chemical group [H]C1=C([H])C([H])=C(*)N=N1 0.000 description 1
125000004940 pyridazin-4-yl group Chemical group N1=NC=C(C=C1)* 0.000 description 1
125000004943 pyrimidin-6-yl group Chemical group N1=CN=CC=C1* 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
238000010992 reflux Methods 0.000 description 1
238000011160 research Methods 0.000 description 1
230000007017 scission Effects 0.000 description 1
125000003548 sec-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
125000003607 serino group Chemical class [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
238000003797 solvolysis reaction Methods 0.000 description 1
208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
229960005202 streptokinase Drugs 0.000 description 1
125000003107 substituted aryl group Chemical group 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
125000000542 sulfonic acid group Chemical group 0.000 description 1
239000011975 tartaric acid Substances 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
125000003944 tolyl group Chemical group 0.000 description 1
YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
WTVXIBRMWGUIMI-UHFFFAOYSA-N trifluoro($l^{1}-oxidanylsulfonyl)methane Chemical group [O]S(=O)(=O)C(F)(F)F WTVXIBRMWGUIMI-UHFFFAOYSA-N 0.000 description 1
229960005356 urokinase Drugs 0.000 description 1
125000003774 valeryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D211/74—Oxygen atoms
- C07D211/76—Oxygen atoms attached in position 2 or 6
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Pain & Pain Management (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Biomedical Technology (AREA)
Oncology (AREA)
Diabetes (AREA)
Hematology (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Rheumatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Hydrogenated Pyridines (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

ZA200401800A 2001-08-08 2004-03-04 Phenyl derivatives as factor Xa inhibitors. ZA200401800B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
DE10139060A DE10139060A1 (de)	2001-08-08	2001-08-08	Phenylderivate

Publications (1)

Publication Number	Publication Date
ZA200401800B true ZA200401800B (en)	2005-02-04

Family

ID=7694867

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA200401800A ZA200401800B (en)	2001-08-08	2004-03-04	Phenyl derivatives as factor Xa inhibitors.

Country Status (17)

Country	Link
US (1)	US7902223B2 (pl)
EP (1)	EP1414456B1 (pl)
JP (1)	JP4409941B2 (pl)
KR (1)	KR20040020061A (pl)
CN (1)	CN1538845A (pl)
AT (1)	ATE538792T1 (pl)
AU (1)	AU2002325882B2 (pl)
BR (1)	BR0211737A (pl)
CA (1)	CA2456717C (pl)
DE (1)	DE10139060A1 (pl)
ES (1)	ES2377497T3 (pl)
HU (1)	HUP0401405A2 (pl)
MX (1)	MXPA04001121A (pl)
PL (1)	PL367960A1 (pl)
RU (1)	RU2004106784A (pl)
WO (1)	WO2003013531A1 (pl)
ZA (1)	ZA200401800B (pl)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE10238002A1 (de) *	2002-08-20	2004-03-04	Merck Patent Gmbh	Benzimidazolderivate
WO2004031145A2 (en) *	2002-10-02	2004-04-15	Bristol-Myers Squibb Company	Lactam-containing diaminoalkyl, beta-aminoacids, alpha-aminoacids and derivatives thereof as factor xa inhibitors
US7144895B2 (en)	2003-02-11	2006-12-05	Bristol-Myers Squibb Co.	Benzene acetamide compounds useful as serine protease inhibitors
EP1594505A4 (en)	2003-02-11	2008-08-13	Bristol Myers Squibb Co	PHENYLGLYCIN DERIVATIVES USEFUL AS SERINE PROTEASE INHIBITORS
TW200505894A (en)	2003-08-08	2005-02-16	Yamanouchi Pharma Co Ltd	Tetrahydro-2H-thiopyran-4-carboxamide derivative
DE602006016566D1 (de)	2005-01-10	2010-10-14	Bristol Myers Squibb Co	Als antikoagulanzien verwendbare phenylglycinamid-derivate
US7456195B2 (en)	2005-06-24	2008-11-25	Bristol-Myers Squibb Company	Phenylglycinamide and pyridylglycinamide derivatives useful as anticoagulants
WO2007022946A1 (de)	2005-08-21	2007-03-01	Abbott Gmbh & Co. Kg	Heterocyclische verbindungen und ihre verwendung als bindungspartner für 5-ht5-rezeptoren

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3279880A (en) *	1965-07-12	1966-10-18	Eastman Kodak Co	Polyester textile material dyed with 1-hydroxy-4-n-p-(2'-pyrrolidonyl-1-) phenyl-amino anthraquinones
DE2815820A1 (de) *	1977-04-15	1978-10-26	Ciba Geigy Ag	Neue n-phenylsubstituierte n-heterocyclen, ihre herstellung und verwendung in mitteln zur beeinflussung des pflanzenwachstums
ZA928276B (en)	1991-10-31	1993-05-06	Daiichi Seiyaku Co	Aromatic amidine derivates and salts thereof.
IL115420A0 (en)	1994-09-26	1995-12-31	Zeneca Ltd	Aminoheterocyclic derivatives
US5612353A (en)	1995-06-07	1997-03-18	Rhone-Poulenc Rorer Pharmaceuticals Inc.	Substituted (sulfinic acid, sulfonic acid, sulfonylamino or sulfinylamino) N-[(aminoiminomethyl)phenylalkyl]-azaheterocyclylamide compounds
DE19530996A1 (de)	1995-08-23	1997-02-27	Boehringer Mannheim Gmbh	Cyclische Guanidine, Verfahren zu ihrer Herstellung und Arzneimittel
AU730224B2 (en)	1996-12-23	2001-03-01	Du Pont Pharmaceuticals Company	Nitrogen containing heteroaromatics as factor Xa inhibitors
AU5283700A (en)	1999-05-24	2000-12-12	Cor Therapeutics, Inc.	Inhibitors of factor xa
AU5284000A (en)	1999-05-24	2000-12-12	Cor Therapeutics, Inc.	Inhibitors of factor xa
CA2374947A1 (en) *	1999-05-24	2000-11-30	Robert M. Scarborough	Inhibitors of factor xa
JP2003500382A (ja)	1999-05-24	2003-01-07	シーオーアールセラピューティクスインコーポレイテッド	Ｘａ因子の阻害剤
DE10102322A1 (de)	2001-01-19	2002-07-25	Merck Patent Gmbh	Phenylderivate

2001
- 2001-08-08 DE DE10139060A patent/DE10139060A1/de not_active Withdrawn
2002
- 2002-07-12 CA CA2456717A patent/CA2456717C/en not_active Expired - Fee Related
- 2002-07-12 HU HU0401405A patent/HUP0401405A2/hu unknown
- 2002-07-12 EP EP02760242A patent/EP1414456B1/de not_active Expired - Lifetime
- 2002-07-12 MX MXPA04001121A patent/MXPA04001121A/es unknown
- 2002-07-12 AU AU2002325882A patent/AU2002325882B2/en not_active Ceased
- 2002-07-12 PL PL02367960A patent/PL367960A1/pl unknown
- 2002-07-12 ES ES02760242T patent/ES2377497T3/es not_active Expired - Lifetime
- 2002-07-12 CN CNA028154827A patent/CN1538845A/zh active Pending
- 2002-07-12 WO PCT/EP2002/007798 patent/WO2003013531A1/de not_active Ceased
- 2002-07-12 US US10/486,238 patent/US7902223B2/en not_active Expired - Fee Related
- 2002-07-12 RU RU2004106784/04A patent/RU2004106784A/ru not_active Application Discontinuation
- 2002-07-12 KR KR10-2003-7016957A patent/KR20040020061A/ko not_active Withdrawn
- 2002-07-12 BR BR0211737-1A patent/BR0211737A/pt not_active IP Right Cessation
- 2002-07-12 AT AT02760242T patent/ATE538792T1/de active
- 2002-07-12 JP JP2003518540A patent/JP4409941B2/ja not_active Expired - Fee Related
2004
- 2004-03-04 ZA ZA200401800A patent/ZA200401800B/en unknown

Also Published As

Publication number	Publication date
MXPA04001121A (es)	2004-05-20
US7902223B2 (en)	2011-03-08
US20040235828A1 (en)	2004-11-25
ATE538792T1 (de)	2012-01-15
ES2377497T3 (es)	2012-03-28
DE10139060A1 (de)	2003-02-20
AU2002325882B2 (en)	2007-05-17
RU2004106784A (ru)	2005-07-27
JP2005501075A (ja)	2005-01-13
BR0211737A (pt)	2004-09-28
HUP0401405A2 (hu)	2004-12-28
CA2456717C (en)	2012-01-03
CA2456717A1 (en)	2003-02-20
CN1538845A (zh)	2004-10-20
EP1414456A1 (de)	2004-05-06
EP1414456B1 (de)	2011-12-28
JP4409941B2 (ja)	2010-02-03
PL367960A1 (pl)	2005-03-07
WO2003013531A1 (de)	2003-02-20
KR20040020061A (ko)	2004-03-06

Publication	Publication Date	Title
CA2434937C (en)	2010-11-09	Phenyl derivatives
US20040038858A1 (en)	2004-02-26	Carboxamide derivatives and their use in the treatment of thromboembolic diseases and tumours
AU2002227993A1 (en)	2003-02-13	Phenyl derivatives
ZA200308028B (en)	2005-01-17	Phenyl derivatives 3.
US20050203127A1 (en)	2005-09-15	2-(Phenyl)-2h-pyrazole-3-carboxylic acid-n-4-(thioxo-heterocyclyl)-phenyl-amide derivatives and corresponding imino-heterocyclyl derivatives and relates compounds for use as inhibitors of the coagulation factors xa and/or viia for treating thromboses
ZA200401800B (en)	2005-02-04	Phenyl derivatives as factor Xa inhibitors.
US20050176760A1 (en)	2005-08-11	N-'4-(2-imino-pyrrolidin-1-yl)phenyl!-acetamide and corresponding piperidine derivatives as factor xa inhibitors for the treatment of thrombo-embolic diseases
US7199133B2 (en)	2007-04-03	Derivatives of phenoxy-n-′4-(isothiazolindin-1, 1-dioxid-2yl)phenyll-valerian-acid amide and other compounds as inhibitors of the coagulation factor xa in the treatment of thromboembolic diseases and tumors
US6943179B2 (en)	2005-09-13	Biurethane derivatives
US20030176465A1 (en)	2003-09-18	Cyclic amino acid derivatives
ZA200301471B (en)	2004-06-29	N-substituted 1-amino-1,1-dialkylcarboxylic acid derivatives.
US20040092517A1 (en)	2004-05-13	Phenyl derivatives and their use in the treatment of thromboembolic disorders or tumours
ZA200400486B (en)	2004-10-13	Carbohydrate derivatives.
US20050119316A1 (en)	2005-06-02	Semicarbazide derivatives and the use thereof as antithrombotics
AU2002250878A1 (en)	2002-09-19	Phenyl derivatives and their use in the treatment of thromboembolic disorders or tumours
ZA200301633B (en)	2004-06-22	Acetamide derivatives and the use thereof as inhibitors of coagulation factor Xa and Vlla.
AU2002249246A1 (en)	2002-10-03	Phenyl derivatives 3
ZA200301638B (en)	2004-06-22	Urethane derivatives.